Arch Venture Fund X, L.p. - Net Worth and Insider Trading
Arch Venture Fund X, L.p. Net Worth
The estimated net worth of Arch Venture Fund X, L.p. is at least $334 Million dollars as of 2024-11-13. Arch Venture Fund X, L.p. is the 10% Owner of Neumora Therapeutics Inc and owns about 29,545,420 shares of Neumora Therapeutics Inc (NMRA) stock worth over $334 Million. Details can be seen in Arch Venture Fund X, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Arch Venture Fund X, L.p. has not made any transactions after 2023-09-19 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Arch Venture Fund X, L.p.
Arch Venture Fund X, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Arch Venture Fund X, L.p. owns 5 companies in total, including Erasca Inc (ERAS) , Sana Biotechnology Inc (SANA) , and Verve Therapeutics Inc (VERV) among others .
Click here to see the complete history of Arch Venture Fund X, L.p.’s form 4 insider trades.
Insider Ownership Summary of Arch Venture Fund X, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ERAS | Erasca Inc | 2021-07-15 | 10 percent owner |
| SANA | Sana Biotechnology Inc | 2021-02-03 | 10 percent owner |
| VERV | Verve Therapeutics Inc | 2021-06-16 | 10 percent owner |
 | | 2022-10-19 | 10 percent owner |
| | 2023-09-19 | 10 percent owner |
Arch Venture Fund X, L.p. Latest Holdings Summary
Arch Venture Fund X, L.p. currently owns a total of 1 stock. Arch Venture Fund X, L.p. owns 29,545,420 shares of Neumora Therapeutics Inc (NMRA) as of September 19, 2023, with a value of $334 Million.
Latest Holdings of Arch Venture Fund X, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NMRA | Neumora Therapeutics Inc | 2023-09-19 | 29,545,420 | 11.31 | 334,158,700 |
Holding Weightings of Arch Venture Fund X, L.p.
Arch Venture Fund X, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Arch Venture Fund X, L.p. has made a total of 1 transactions in Neumora Therapeutics Inc (NMRA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Neumora Therapeutics Inc is the acquisition of 1,500,000 shares on September 19, 2023, which cost Arch Venture Fund X, L.p. around $26 Million.
Insider Trading History of Arch Venture Fund X, L.p.
- 1
Arch Venture Fund X, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Arch Venture Fund X, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Arch Venture Fund X, L.p. is 21.45%. GuruFocus also compares Arch Venture Fund X, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Arch Venture Fund X, L.p. within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Arch Venture Fund X, L.p.'s insider trading performs compared to the benchmark.
Performance of Arch Venture Fund X, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -17.28 | | | | | |
| Relative Return to S&P 500(%) | -13.55 | | | | | |
Arch Venture Fund X, L.p. Ownership Network
Ownership Network List of Arch Venture Fund X, L.p.
Ownership Network Relation of Arch Venture Fund X, L.p.
Arch Venture Fund X, L.p. Owned Company Details
What does Erasca Inc do?
Who are the key executives at Erasca Inc?
Arch Venture Fund X, L.p. is the 10 percent owner of Erasca Inc. Other key executives at Erasca Inc include director & 10 percent owner & See Remarks Jonathan E Lim , Chief Medical Officer Shannon Morris , and General Counsel Ebun Garner .
Erasca Inc (ERAS) Insider Trades Summary
Over the past 18 months, Arch Venture Fund X, L.p. made no insider transaction in Erasca Inc (ERAS). Other recent insider transactions involving Erasca Inc (ERAS) include a net purchase of 2,100,000 shares made by Jonathan E Lim , a net purchase of 110,000 shares made by Alexander W. Casdin , and a net purchase of 10,000 shares made by Start Valerie Denise Harding .
In summary, during the past 3 months, insiders sold 0 shares of Erasca Inc (ERAS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Erasca Inc (ERAS) were sold and 2,220,000 shares were bought by its insiders, resulting in a net purchase of 2,220,000 shares.
Erasca Inc (ERAS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Erasca Inc Insider Transactions
Arch Venture Fund X, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Arch Venture Fund X, L.p.. You might contact Arch Venture Fund X, L.p. via mailing address: 8755 W. Higgins Road, Suite 1025, Chicago Il 60631.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
